
|Articles|January 1, 2006
Experts weigh benefits, risks of Allergan-Inamed merger
National report — A proposed $3.2 billion merger of Botox-maker Allergan and breast-implant maker Inamed would ultimately benefit dermatologists, an Allergan official says.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














